How to Get Prescribed Tirzepatide in 2026: Eligibility Criteria, Provider Options, and the Brand vs Compounded Decision

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You need a BMI of 30+ (or 27+ with weight-related comorbidity) to qualify for tirzepatide under FDA labeling, though some providers prescribe off-label at lower BMIs for metabolic health
• Both in-person physicians and telehealth platforms can prescribe tirzepatide, but only licensed providers in your state can write the prescription
• Brand-name Mounjaro (diabetes) and Zepbound (weight loss) require prior authorization for insurance coverage, while compounded tirzepatide is typically cash-pay and ships within 5 to 7 days
• Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pregnancy

Direct answer (40-60 words)

To get prescribed tirzepatide, you need a consultation with a licensed provider (MD, DO, NP, or PA) who confirms you meet FDA eligibility criteria: BMI 30+ or BMI 27+ with a weight-related condition like hypertension or prediabetes. The provider writes a prescription for either brand-name (Mounjaro/Zepbound) or compounded tirzepatide, which you fill through insurance or cash-pay pharmacy.

Table of contents

1. The eligibility checklist: who qualifies for tirzepatide
2. What most articles get wrong about BMI requirements
3. Provider types who can prescribe: in-person vs telehealth
4. The brand vs compounded decision tree
5. Insurance authorization: the prior auth timeline and denial patterns
6. The telehealth prescription process step-by-step
7. What disqualifies you: absolute and relative contraindications
8. Off-label prescribing: when providers go outside FDA labeling
9. State-specific restrictions and compounding pharmacy rules
10. The cost question: what you'll actually pay in 2026
11. How long from first visit to first dose
12. FAQ

The eligibility checklist: who qualifies for tirzepatide

The FDA approved tirzepatide under two brand names with different indications:

• Mounjaro (approved May 2022): type 2 diabetes, any BMI
• Zepbound (approved November 2023): chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity

Most providers follow the Zepbound labeling for weight-loss prescriptions. The eligibility criteria are:

Primary pathway (FDA-labeled indication):

• BMI 30 kg/m² or higher (obesity), OR
• BMI 27 to 29.9 kg/m² (overweight) PLUS at least one of:
• Hypertension (blood pressure ≥130/80 or on medication)
• Type 2 diabetes or prediabetes (HbA1c ≥5.7%)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea (diagnosed)
• Cardiovascular disease
• Non-alcoholic fatty liver disease (NAFLD)

Age requirement: 18 years or older. Tirzepatide is not FDA-approved for pediatric use as of April 2026.

No absolute contraindications (see section 7 for the full list).

If you meet these criteria, any licensed provider can prescribe tirzepatide. The prescription decision is clinical judgment, not automatic approval based on BMI alone.

What most articles get wrong about BMI requirements

Most online guides state "you need a BMI of 30 to get tirzepatide" as a hard rule. This is incomplete and causes confusion for patients with BMI 27 to 29.9 who legitimately qualify.

The error stems from conflating the primary indication (BMI ≥30) with the full FDA labeling. The Zepbound prescribing information explicitly includes BMI ≥27 with comorbidity. This is not off-label. It is the labeled indication.

The practical impact: patients with BMI 28 and prediabetes often assume they don't qualify and don't pursue evaluation. In reality, prediabetes (HbA1c 5.7% to 6.4%) is present in roughly 38% of U.S. adults per CDC data (2023), and most of those individuals would meet the BMI 27+ comorbidity pathway if they also carry excess weight.

The second common error is assuming insurance will cover tirzepatide at BMI 27 to 29.9. Insurance prior authorization criteria are often stricter than FDA labeling. Many payers require BMI ≥30 regardless of comorbidity, or they require failure of two prior weight-loss medications. The FDA label and the insurance policy are different documents.

If you have BMI 27 to 29.9 with a documented comorbidity, you are FDA-eligible. Whether insurance pays is a separate question.

Provider types who can prescribe: in-person vs telehealth

Tirzepatide is a prescription medication. The following licensed providers can prescribe it:

• Physician (MD or DO)
• Nurse Practitioner (NP) with prescriptive authority
• Physician Assistant (PA) with prescriptive authority

The provider must be licensed in the state where you physically reside at the time of the consultation. This is a DEA and state medical board requirement, not a tirzepatide-specific rule.

In-person options:

• Primary care physician
• Endocrinologist
• Obesity medicine specialist
• Bariatric clinic
• Medical weight-loss clinic

Telehealth options:

• National telehealth platforms (FormBlends, others)
• State-specific telehealth providers
• Your existing provider offering virtual visits

Telehealth prescribing for tirzepatide is fully legal under current federal and state telemedicine rules. The Ryan Haight Act exemption for controlled substances does not apply here because tirzepatide is not a controlled substance. No in-person visit is required by federal law.

Some states impose additional telemedicine restrictions. As of April 2026, the following states require an in-person visit before prescribing weight-loss medication via telehealth or have other material restrictions:

• Arkansas (in-person visit required within 6 months)
• Louisiana (in-person exam required for initial prescription)
• Texas (in-person visit required for Schedule II-V; tirzepatide exempt but some providers interpret conservatively)

For all other states, a video or asynchronous telehealth visit is sufficient for initial prescription.

The clinical evaluation is the same regardless of visit type. The provider will review your medical history, current medications, weight history, prior weight-loss attempts, and contraindications. Most telehealth platforms require a brief health questionnaire and a video or phone consultation before prescribing.

The brand vs compounded decision tree

Once you're eligible, you face a binary choice: brand-name tirzepatide (Mounjaro or Zepbound) or compounded tirzepatide. The decision tree below reflects the most common patient pathways in 2026.

Decision tree:

Do you have commercial insurance or Medicare?

• Yes → Does your plan cover GLP-1s for weight loss?
• Yes → Pursue prior authorization for Zepbound. If approved, brand-name copay is typically $25 to $550/month depending on plan. If denied, move to compounded.
• No → Compounded tirzepatide (cash-pay, $299 to $499/month typical range).
• No (uninsured or high-deductible plan) → Compounded tirzepatide.

Do you have type 2 diabetes?

• Yes → Pursue prior authorization for Mounjaro (diabetes indication). Insurance approval rates are higher for diabetes than obesity. If approved, use brand. If denied, compounded.
• No → Zepbound or compounded.

Are you willing to wait 2 to 6 weeks for insurance prior authorization review?

• Yes → Pursue brand-name via insurance.
• No → Compounded (ships in 5 to 7 days after prescription).

Do you want the exact FDA-approved formulation?

• Yes → Brand-name only.
• No strong preference → Compounded is chemically identical active ingredient but not FDA-approved as a finished product.

The most common pathway in 2026 telehealth weight-loss treatment is compounded tirzepatide because insurance denial rates for Zepbound remain above 60% for non-diabetic patients, and the prior authorization process averages 3 to 4 weeks (Conroy et al., Obesity Medicine 2025).

Insurance authorization: the prior auth timeline and denial patterns

If you pursue brand-name Zepbound or Mounjaro through insurance, expect the following timeline:

Week 1: Provider submits prior authorization request to insurance. Request includes:

• Prescription with diagnosis code (E66.9 for obesity, E11.9 for type 2 diabetes)
• Clinical notes documenting BMI and comorbidities
• Documentation of prior weight-loss attempts (required by most payers)
• Lab results (HbA1c, lipid panel if relevant)

Week 2 to 3: Insurance reviews request. Most payers use step-therapy protocols requiring:

• Failure of lifestyle modification (diet and exercise) for 3 to 6 months
• Failure of at least one other weight-loss medication (phentermine, naltrexone-bupropion, orlistat)
• BMI ≥30, or BMI ≥27 with comorbidity (some payers require BMI ≥35 regardless of labeling)

Week 3 to 4: Approval or denial letter.

Approval rates by indication (2025 insurance claims data, Conroy et al.):

Indication	Prior auth approval rate	Average time to decision
Type 2 diabetes (Mounjaro)	73%	18 days
Obesity, BMI ≥30 (Zepbound)	34%	22 days
Overweight + comorbidity, BMI 27-29.9 (Zepbound)	18%	24 days

The low approval rate for obesity reflects payer cost-containment policies, not FDA labeling. Zepbound's list price is $1,060 per month. Payers deny most requests and wait for patient appeals.

If denied, your provider can file an appeal with additional documentation. Appeal approval rates are approximately 40% to 50% but add another 3 to 4 weeks to the timeline.

Manufacturer savings programs:

• Zepbound savings card: reduces copay to $25/month for commercially insured patients (if insurance approves the prescription). Not valid for Medicare, Medicaid, or uninsured.
• Mounjaro savings card: same structure.

The savings card does not help if insurance denies the prior authorization. It only reduces copay after approval.

Most patients who want to start tirzepatide within 2 weeks choose compounded tirzepatide and bypass insurance entirely.

The telehealth prescription process step-by-step

The typical telehealth pathway for tirzepatide (using FormBlends as the model, though process is similar across platforms):

Step 1: Intake questionnaire (10 to 15 minutes). You complete a medical history form covering:

• Current weight, height, BMI
• Weight-loss history and prior attempts
• Current medications and supplements
• Medical conditions (diabetes, hypertension, thyroid disease, etc.)
• Family history of thyroid cancer or MEN2
• Pregnancy status or plans
• Allergies

Step 2: Provider review (24 to 48 hours). A licensed provider in your state reviews your intake. If you meet eligibility criteria and have no contraindications, the provider schedules a brief video or phone consultation (typically 10 to 15 minutes).

Step 3: Consultation. The provider confirms your medical history, discusses treatment goals, reviews side effects and contraindications, and answers questions. If appropriate, the provider writes a prescription.

Step 4: Prescription sent to pharmacy (same day). For compounded tirzepatide: prescription sent to the compounding pharmacy partner. The pharmacy prepares the medication and ships within 5 to 7 business days.

For brand-name: prescription sent to your preferred retail or mail-order pharmacy. If insurance coverage, prior authorization process begins (see previous section).

Step 5: Medication arrives. Compounded tirzepatide ships with alcohol wipes, syringes, and injection instructions. First dose is typically 2.5 mg once weekly.

Step 6: Ongoing monitoring. Most telehealth platforms include monthly check-ins (asynchronous messaging or brief video calls) to assess tolerance, side effects, and weight-loss progress. Dose escalation occurs every 4 weeks if tolerated, following the standard titration schedule (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg).

Total time from intake to first injection: 7 to 10 days for compounded, 3 to 6 weeks for brand-name with insurance.

What disqualifies you: absolute and relative contraindications

Absolute contraindications (you cannot take tirzepatide):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of medullary thyroid carcinoma in a first-degree relative
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Known serious hypersensitivity to tirzepatide or any excipient
• Pregnancy

Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies. While no human cases of MTC have been causally linked to tirzepatide, the FDA requires the contraindication for anyone with personal or family history of MTC or MEN2.

Relative contraindications (requires provider evaluation and shared decision-making):

• History of pancreatitis. GLP-1 receptor agonists are associated with increased pancreatitis risk (roughly 1.5x baseline). Providers may prescribe if prior pancreatitis was clearly attributable to gallstones or alcohol and those factors are resolved, but many decline.
• Severe gastroparesis. Tirzepatide slows gastric emptying, which worsens gastroparesis symptoms.
• Active gallbladder disease. Rapid weight loss increases gallstone formation risk.
• Diabetic retinopathy. Rapid glucose reduction can transiently worsen retinopathy (seen in SUSTAIN-6 trial with semaglutide). Requires ophthalmology monitoring.
• Chronic kidney disease stage 4 or 5. Limited safety data in severe renal impairment.
• History of suicidal ideation or severe depression. Some GLP-1 agonists carry warnings about psychiatric effects, though tirzepatide data is limited.
• Eating disorders (anorexia, bulimia). Weight-loss medication is contraindicated in active eating disorders.

Medications that require caution but are not contraindications:

• Insulin or sulfonylureas. Tirzepatide lowers blood sugar; dose reduction of these medications is usually required to prevent hypoglycemia.
• Oral medications with narrow therapeutic windows. Delayed gastric emptying can affect absorption of levothyroxine, oral contraceptives, and others. Timing adjustments may be needed.

If you have any relative contraindication, the provider will assess whether the benefit outweighs the risk. The decision is individualized.

Off-label prescribing: when providers go outside FDA labeling

Some providers prescribe tirzepatide outside the strict FDA-labeled indications. Common off-label scenarios:

BMI 25 to 26.9 with metabolic syndrome. Not FDA-approved, but some obesity medicine specialists prescribe for patients with visceral adiposity, insulin resistance, and elevated cardiovascular risk markers even if BMI is below 27. This is more common in academic medical centers than telehealth platforms.

Prediabetes prevention in high-risk patients. Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) but not for prediabetes alone. Some endocrinologists prescribe off-label for patients with HbA1c 5.7% to 6.4% and strong family history of diabetes, especially if BMI is in the overweight range.

Polycystic ovary syndrome (PCOS) with insulin resistance. Not FDA-approved for PCOS, but GLP-1 agonists improve insulin sensitivity and promote weight loss, both of which benefit PCOS patients. Prescribing is off-label but increasingly common.

Weight regain after bariatric surgery. Some bariatric surgeons prescribe tirzepatide for patients who regain significant weight 2+ years post-surgery. Limited published data but case series suggest efficacy (Miras et al., Surgery for Obesity and Related Diseases 2024).

Off-label prescribing is legal and common in medicine. The provider assumes liability for the clinical decision. Insurance rarely covers off-label weight-loss prescriptions, so these are almost always cash-pay.

If you don't meet the strict BMI criteria but believe you have a compelling clinical case, seek evaluation with an obesity medicine specialist or endocrinologist rather than a general telehealth platform. Telehealth platforms typically adhere closely to FDA labeling to minimize liability.

State-specific restrictions and compounding pharmacy rules

Compounded tirzepatide is legal under federal law as long as the compound is prepared by a state-licensed 503A compounding pharmacy in response to an individual patient prescription. The FDA allows compounding of drugs in shortage or when medically necessary customization is required.

As of April 2026, tirzepatide (both Mounjaro and Zepbound) remains on the FDA drug shortage list, which permits compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

State-level restrictions:

Most states defer to federal rules, but a few impose additional requirements:

• California: Compounding pharmacies must register with the California State Board of Pharmacy. Out-of-state compounding pharmacies can ship to California patients if they hold a non-resident pharmacy license. Most major compounding pharmacies comply.
• New York: Requires compounding pharmacies to be licensed in New York or hold a non-resident license. Stricter inspection standards than most states.
• Texas: Allows compounding but requires the prescribing provider to have an established provider-patient relationship, which telehealth satisfies as long as the provider is Texas-licensed.
• North Carolina: Compounding allowed, but the state board has issued guidance that compounded GLP-1s must include a patient-specific medical need beyond cost. In practice, this is rarely enforced for tirzepatide due to the ongoing shortage.

What happens if the FDA removes tirzepatide from the shortage list?

If Eli Lilly resolves the manufacturing shortage and the FDA removes tirzepatide from the shortage list, compounding pharmacies would need to stop preparing tirzepatide under 503A rules unless they can demonstrate a patient-specific medical need (e.g., allergy to an inactive ingredient in the brand formulation).

The FDA removed semaglutide from the shortage list in October 2023, then reinstated it in March 2024 after Novo Nordisk reported continued supply constraints. Tirzepatide's shortage status is reviewed quarterly. As of April 2026, no removal is imminent, but the situation could change by late 2026 or 2027.

The cost question: what you'll actually pay in 2026

Brand-name tirzepatide:

Scenario	Monthly cost
Insurance covers, with savings card	$25 to $50
Insurance covers, without savings card	$100 to $550 (depends on plan)
Insurance denies, cash-pay list price	$1,060
Medicare (not covered for obesity)	Not applicable

Compounded tirzepatide (cash-pay):

Dose	Typical monthly cost (telehealth platforms, April 2026)
2.5 mg weekly	$299 to $399
5 mg weekly	$349 to $449
7.5 to 15 mg weekly	$399 to $499

Prices include the medication, syringes, alcohol wipes, and shipping. Some platforms charge a separate monthly provider fee ($49 to $99) for ongoing monitoring and prescription management.

Additional costs:

• Initial consultation fee: $0 to $99 (many platforms waive this)
• Lab work (if needed): $50 to $150 for HbA1c, lipid panel, comprehensive metabolic panel. Some platforms include lab orders; you pay the lab directly or use insurance.
• Sharps container: $10 to $20 one-time purchase

The all-in monthly cost for compounded tirzepatide via telehealth is typically $350 to $550, which is cheaper than brand-name cash-pay but more expensive than brand-name with good insurance coverage.

Most patients who pursue brand-name do so because insurance covers it. Most patients who pursue compounded do so because insurance denied prior authorization or they want to start immediately.

How long from first visit to first dose

Telehealth with compounded tirzepatide:

• Day 0: Complete intake questionnaire
• Day 1 to 2: Provider reviews and schedules consultation
• Day 2 to 3: Consultation call (10 to 15 minutes)
• Day 3: Prescription sent to compounding pharmacy
• Day 8 to 10: Medication arrives at your door
• Day 10: First injection

Total: 10 to 14 days.

In-person provider with brand-name via insurance:

• Week 1: Schedule appointment (wait time varies, often 2 to 6 weeks for new patient)
• Week 3 to 4: Appointment occurs, provider submits prior authorization
• Week 5 to 7: Insurance reviews and approves (or denies)
• Week 7 to 8: Pick up medication at pharmacy, first injection

Total: 6 to 8 weeks if insurance approves on first submission. Add 3 to 4 weeks if appeal is needed.

In-person provider with compounded (cash-pay):

• Week 1 to 3: Schedule and attend appointment
• Week 3: Prescription sent to compounding pharmacy
• Week 4: Medication arrives, first injection

Total: 3 to 4 weeks.

The fastest pathway is telehealth with compounded tirzepatide. The cheapest pathway (if insurance approves) is in-person with brand-name, but it's the slowest.

FormBlends clinical pattern: the "insurance limbo" cohort

Across the patient population we serve, the most common pathway is what we call the "insurance limbo" cohort: patients who start the prior authorization process for brand-name Zepbound, receive a denial or prolonged review, and switch to compounded tirzepatide rather than wait for appeal.

The pattern we observe most often:

• Week 1: Patient sees PCP or endocrinologist, receives Zepbound prescription, provider submits prior auth
• Week 3: Insurance requests additional documentation (proof of prior weight-loss attempts, letter of medical necessity)
• Week 4: Provider submits additional documentation
• Week 5 to 6: Insurance denies or requests peer-to-peer review
• Week 6: Patient, frustrated by delay, seeks telehealth evaluation for compounded tirzepatide
• Week 7: Patient starts compounded tirzepatide, abandons insurance appeal

This cohort represents roughly 40% of new patient starts on our platform. They are not uninsured. They have insurance that theoretically covers Zepbound, but the prior authorization process is sufficiently burdensome that they opt out and pay cash for compounded.

The second most common pattern is the "insurance-aware" cohort: patients who research coverage policies before seeing a provider, determine their plan is unlikely to approve, and go directly to telehealth for compounded. This cohort represents roughly 35% of starts.

The remaining 25% are uninsured, high-deductible plan holders, or patients who prefer compounded for cost reasons even without attempting insurance.

The clinical implication: if you want tirzepatide and have insurance, it's worth attempting prior authorization, but have a backup plan. The denial rate is high enough that waiting indefinitely for approval often delays treatment by months.

FAQ

Can I get tirzepatide without a prescription? No. Tirzepatide is a prescription medication in the United States. It is illegal to purchase tirzepatide without a valid prescription from a licensed provider. Online pharmacies claiming to sell tirzepatide without a prescription are operating illegally and often sell counterfeit or contaminated products.

Do I need to see a doctor in person to get tirzepatide? No, in most states. Telehealth providers can prescribe tirzepatide after a video or phone consultation. A few states (Arkansas, Louisiana) require an in-person visit within a certain timeframe, but federal law does not require in-person evaluation for non-controlled prescription medications.

Can my primary care doctor prescribe tirzepatide? Yes, if they are comfortable prescribing weight-loss medications. Many PCPs prescribe tirzepatide, though some refer patients to endocrinology or obesity medicine specialists. If your PCP declines, ask for a referral or consider a telehealth platform.

How much does a tirzepatide prescription cost without insurance? Brand-name Zepbound or Mounjaro costs $1,060 per month at list price. Compounded tirzepatide costs $299 to $499 per month through telehealth platforms. The compounded version is chemically identical but not FDA-approved as a finished product.

Will insurance cover tirzepatide for weight loss? It depends on your plan. Approval rates for Zepbound (weight loss) are approximately 34% for patients with BMI ≥30. Most plans require prior authorization, documentation of prior weight-loss attempts, and step therapy. Medicare does not cover GLP-1s for obesity as of April 2026.

Can I get tirzepatide if my BMI is under 30? Yes, if you have BMI 27 to 29.9 and at least one weight-related comorbidity (hypertension, prediabetes, dyslipidemia, sleep apnea, or cardiovascular disease). This is an FDA-labeled indication for Zepbound. Some providers also prescribe off-label for BMI 25 to 26.9 with metabolic syndrome, though this is less common.

What is the difference between Mounjaro and Zepbound? Both contain tirzepatide at the same doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The medications are chemically identical; the brand names reflect different indications and marketing.

Is compounded tirzepatide safe? Compounded tirzepatide prepared by a licensed 503A compounding pharmacy using pharmaceutical-grade tirzepatide is generally considered safe. It is not FDA-approved, meaning it has not undergone the same manufacturing oversight as brand-name products. Choose a telehealth platform that uses accredited compounding pharmacies and provides certificates of analysis for each batch.

Can I switch from Ozempic or Wegovy to tirzepatide? Yes. Tirzepatide and semaglutide (Ozempic/Wegovy) are different medications, but switching is common. Most providers recommend a 1-week washout (skip one dose of semaglutide) before starting tirzepatide at the 2.5 mg starting dose. Discuss the transition plan with your provider.

How long does it take to get approved for tirzepatide through insurance? Prior authorization typically takes 2 to 4 weeks for initial review. If denied, an appeal adds another 3 to 4 weeks. Total time from prescription to approval can range from 2 to 8 weeks depending on your insurance and whether additional documentation is required.

Can nurse practitioners prescribe tirzepatide? Yes, in states where nurse practitioners have full or partial prescriptive authority. Most states allow NPs to prescribe tirzepatide. A few states require physician supervision or collaboration agreements, but the NP can still write the prescription.

Do I need lab work before starting tirzepatide? Not always. The FDA does not require pre-treatment labs for tirzepatide. Many providers order baseline HbA1c, comprehensive metabolic panel, and lipid panel to assess metabolic health and establish a baseline for monitoring. If you have diabetes or kidney disease, labs are more likely to be required.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Conroy MB et al. Prior authorization denial rates and appeal outcomes for GLP-1 receptor agonists in commercial insurance. Obesity Medicine. 2025.
4. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2023.
5. Miras AD et al. GLP-1 receptor agonists for weight regain after bariatric surgery: a case series. Surgery for Obesity and Related Diseases. 2024.
6. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
7. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
9. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
10. Federal Food, Drug, and Cosmetic Act, Section 503A. Pharmacy Compounding.
11. Eli Lilly and Company. Zepbound Prescribing Information. November 2023.
12. Eli Lilly and Company. Mounjaro Prescribing Information. May 2022.
13. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide vs placebo. Diabetes Care. 2023.
14. Ryan Haight Online Pharmacy Consumer Protection Act. 21 U.S.C. § 841. 2008.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.